explore -WSS

explore

author：hotspot 2025-10-01 14:19:24 - browse：5

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Group opposing PBM reform sets lobbying record

hotspot

WSS

Medicare to cover more brain scans for Alzheimer’s patients

Key House panel plots a new health care package

How dance can help nurses traumatized by Covid

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Florida babysitter arrested over hot car death, authorities say

WHO calls for emergency meeting on new China virus, as cases spread

knowledge

explore

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How Brent Saunders' Allergan experiment failed

Tori Bowie and the unacceptable rates of Black maternal death

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

FDA approval of Sarepta Duchenne genetic therapy gives me hope

EMA weighs against approval for Mirati's lung cancer drug

Anesthesiologist group: stop taking Ozempic before surgery

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

How one medical school became remarkably diverse

Sanders adds drug shortage policies to pandemic preparedness bill

leisure time

Startup Neumora takes a novel depression drug to Phase 3

In early work, researchers turn to CRISPR to treat Alzheimer's

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

How Medicaid coverage policies for immigrants impact new moms

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

Startup Neumora takes a novel depression drug to Phase 3

knowledge

hotspot

knowledge

knowledge